Targeting PARP in Patients With Breast Cancer - prIME Oncology
Expert Review
Expert Review

Targeting PARP in Patients With Breast Cancer

A Closer Look at Emerging Options

Not a member of My prIME? Join now for instant access.

Gain valuable updates and insight on targeting PARP in your patients with breast cancer, straight from the experts. This activity features an engaging discussion with expert faculty and downloadable slides focused on the rationale for targeting DNA repair, recent clinical trial data, recommendations for the use of PARP inhibitors in clinical practice, and ongoing studies evaluating this therapeutic strategy.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



0.75 AMA PRA Category 1 Credit(s)™

Release Date

Release Date

Apr 15, 2019

Expiration Date

Apr 15, 2020

  • Sara Hurvitz, MD, FACPUCLA Jonsson Comprehensive Cancer Center
    University of California, Los Angeles
    Los Angeles, California, United States
  • Joyce O’Shaughnessy, MDBaylor University Medical Center
    Texas Oncology
    US Oncology
    Dallas, Texas, United States
  • Mark Pegram, MDStanford Comprehensive Cancer Institute
    Stanford University School of Medicine
    Palo Alto, California, United States
  • Rationale and mechanisms of action for PARP inhibitors
  • Testing for BRCA mutations and other defects in DNA repair
  • PARP inhibitors in metastatic breast cancer
  • PARP inhibitors in early breast cancer
  • Combination approaches
  • Ongoing clinical trials

This educational activity is designed to meet the needs of medical oncologists, breast surgeons, and other healthcare providers involved in the management of patients with metastatic breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Identify the mechanism of action for PARP inhibition (PARPi) and the differences between current and emerging PARP inhibitors
  • Describe the role for BRCA1/2 and homologous recombination deficiency (HRD) testing in the management of patients with breast cancer
  • Evaluate current clinical trial data focused on the use of PARPi in the treatment of breast cancer
  • Employ best practices for treatment selection and management of adverse events in patients with BRCA-mutated or “BRCA-like” breast cancer

This educational activity is supported by a grant from Pfizer.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology.   Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 0.75 hour

To contact Postgraduate Institute for Medicine please visit

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Hurvitz has disclosed grant support from Ambryx, Amgen, Bayer, BI Pharma, Biomarin, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GlaxoSmithKline, Lilly, Macrogenics, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, Puma, Roche, Seattle Genetics and travel support from Lilly, Novartis, and OBI Pharma. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr O’Shaughnessy has disclosed that she has received honoraria for consulting and advisory boards for AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Seattle Genetics, and Syndax Pharmaceuticals. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Pegram has disclosed that has received consulting fees from AstraZeneca and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Tristin Abair, PhD (medical writer) – worked on non–CME certified projects in the last 12 months supported by AbbVie Inc, Astellas Pharma Inc., Bayer AG, Novartis International AG, and Jazz Pharmaceuticals
  • Heather Tomlinson, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Clovis Oncology; F. Hoffmann-La Roche Ltd; ImmunoGen; Merck KGaA, Darmstadt, Germany; Pfizer; Novartis Oncology; Puma Biotechnology; and Tesaro

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.